Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 6/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548859 | 0.89 | CCNE2 (0.44) | SCN9AADORA2AADORA1 | |
| SCHEMBL20589214 | 0.89 | CCNE2 (0.44) | SCN9AADORA2AADORA1 | |
| SCHEMBL20589213 | 0.89 | CCNE2 (0.44) | SCN9AADORA2AADORA1 | |
| SCHEMBL20589305 | 0.89 | CCNE2 (0.44) | SCN9AADORA2AADORA1 | |
| SCHEMBL25529900 | 0.77 | SMN1; SMN2 (0.54) | — | |
| SCHEMBL2018756 | 0.72 | JAK3 (0.43) | CRHR1SCN9ANMT1PDE10AADORA2A | |
| SCHEMBL2018758 | 0.72 | JAK3 (0.43) | CRHR1SCN9ANMT1PDE10AADORA2A | |
| SCHEMBL20589654 | 0.71 | ACVR1 (0.51) | PDE10AADORA2AADORA1CNR2 | |
| SCHEMBL20589653 | 0.71 | ACVR1 (0.51) | PDE10AADORA2AADORA1CNR2 | |
| SCHEMBL25214718 | 0.69 | CCNE2 (0.49) | PDE10AADORA2AADORA1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661426-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | CRHR1 4847/4885SCN9A 1582/4885NMT1 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.